Melinda French: Mifepristone remains available for U.S. women and care providers

Melinda French: Mifepristone remains available for U.S. women and care providers
French on U.S. mifepristone access

Access to mifepristone, a key medication used in reproductive care, will continue for women and their healthcare providers in the U.S. for now.

Melinda French expressed her relief at the continued availability of the drug, stating that access to safe and effective medication should not be subject to debate. She also emphasized her support for a woman's right to make decisions concerning her health and future.

French previously commented on the critical role of mifepristone in U.S. women’s health. She has warned that restricting access to the drug could raise health risks for women. The ongoing debate has made the availability of mifepristone a focus for healthcare stakeholders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.